COMMUNIQUÉS West-GlobeNewswire
-
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
11/06/2026 -
Loma Linda University Health and Nudj Health Launch Integrated Whole-Person Primary Care Model Designed to Advance the Future of Healthcare Delivery
11/06/2026 -
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
11/06/2026 -
Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
11/06/2026 -
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
11/06/2026 -
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
11/06/2026 -
Announcing the 2026 Hall of Fame Philadelphia Titan 100 Honorees
11/06/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
11/06/2026 -
Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance
11/06/2026 -
EmblemHealth's Environmental Resilience Program Show Promising Results in Helping New Yorkers Reduce Heat-Related Risks and Hospitalizations
11/06/2026 -
Ally Medical ER Is Headed to Pflugerville
11/06/2026 -
KFSH Advances Practical AI Applications Driving Transformation Across Specialized Healthcare
11/06/2026 -
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
11/06/2026 -
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
11/06/2026 -
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
11/06/2026 -
Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026
11/06/2026 -
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
11/06/2026 -
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
11/06/2026 -
Spinach® is the Number One Vape Brand in Canada
11/06/2026
Pages